Ichnos Glenmark to Present Updated Phase 1 Data on ISB 2001 in Multiple Myeloma at ASH 2026 MM Desk 6 November, 2026 Ichnos Glenmark Innovation, Inc (IGI), a clinical-stage biotechnology company focused on developing multispecific therapeutics in Read More
Ichnos Glenmark Reveals ISB 2301 for Solid Tumors MM Desk 22 May, 2026 Ichnos Glenmark Innovation has announced the development of ISB 2301, a first-in-class multispecific immune cell Read More